The company is a healthcare enterprise with detailed balance sheet, cash flow, and income statement data available, but the unstructured data does not specify its core business activities.


# Company Summary

The provided document does not include specific details about the company's operations, number of customers, employees, revenue, or income. The excerpt lists the contents of the company's filings, such as:

- Item 1: Business
- Item 1A: Risk Factors
- Item 1B: Unresolved Staff Comments
- Item 1C: Cybersecurity
- Item 2: Properties
- Item 3: Legal Proceedings
- Item 4: Mine Safety Disclosures

There is no detailed description of the company's core activities, markets, financial metrics, or organizational details within the provided section. To accurately summarize what the company does, additional information from the Business section or other detailed disclosures would be necessary.


Northwest Biotherapeutics, Inc. is focused on developing immunotherapy products, particularly DCVax®-L for the treatment of brain cancer.

### Northwest Biotherapeutics, Inc. Overview

**Company Profile:**
- **Name:** Northwest Biotherapeutics, Inc.
- **Incorporation:** Delaware
- **Principal Office:** 4800 Montgomery Lane, Suite 800, Bethesda, MD 20814
- **Trading Symbol:** NWBO (OTCQB)

**Business Focus:**
Northwest Biotherapeutics, Inc. specializes in the development of immunotherapy products for the treatment of cancer, particularly using dendritic cell technology. The company's lead product candidate, **DCVax®-L**, is designed to empower the immune system to attack cancer cells. 

### Key Products and Programs:

- **DCVax®-L:** An immune therapy product specifically targeting brain cancer (glioblastoma). 
  - **Regulatory Status:** As of 2024, the company submitted its first application for commercial approval of DCVax®-L to the UK Health Authority.
  
- **Manufacturing Facilities:**
  - **Location:** Sawston, UK (with a GMP facility) for production and related services.
  - **Partnerships:** Works with Advent BioServices, Ltd. for manufacturing and other operational programs related to DCVax-L.

### Financial Details:

- **Employees:** The company operates with a small team. As of 2024, specific employee counts were not disclosed, but the executive team consists of around four key positions.
  
- **Revenue:** The company did not report traditional revenue during this period, as it is heavily involved in development phases and awaiting regulatory approval for its main products.

- **Income:** Comparative income details were not provided. The expected future income would be contingent upon the success of DCVax®-L and potential revenues from regulatory approvals and production contracts.

### Customers:
- **Target Market:** The primary target market includes healthcare providers, hospitals, and specialized cancer treatment clinics focusing on innovative cancer therapies.
- The exact number of customers was not disclosed, but the focus is on a niche market within oncology treatment.

### Market Position:
- **Competitive Advantage:** Northwest Biotherapeutics is positioned in the immuno-oncology space, which is increasingly critical due to the rising demand for personalized cancer treatment options.
- **Intellectual Property:** The company aims to build and expand its intellectual property portfolio, solidifying its position in the field.

### Future Goals:
The company plans to advance its clinical programs and pursue eventual commercialization efforts if it obtains regulatory approvals for its therapies. The anticipated progress of its products could enable significant revenue growth once they are available to the market. 

---
**Note:** Specific numbers related to revenue/funds were not detailed in the provided document, highlighting the company's focus on product development rather than financial metrics at this stage. Details regarding customer count and employee numbers typically reflect operational maturity and established market presence, which may grow post-commercial approval.

NORTHWEST BIOTHERAPEUTICS INC

10-K / March 31, 2025

10-K / April 29, 2024

10-K / March 31, 2025

Company Summary